Aim: Dysregulated apoptosis has been implicated in autoimmune diseases. In the present study, we investigated the apoptosis-related cytokines and apoptosis in patients with primary antiphospholipid syndrome (pAPS).
Method: We prospectively recruited 12 pAPS patients, 17 antiphospholipid antibody (APA)-positive systemic lupus erythematosus (SLE) patients without APS manifestations (APA SLE), 13 SLE patients with secondary APS (APS SLE) and 10 healthy controls (HCs). Plasma levels of soluble apoptosis-inducing ligands and cytokines, and the expression levels of apoptosis-inducing ligands in peripheral blood mononuclear cells, were determined. In addition, blood lymphocytes/monocytes apoptosis were determined in six pAPS patients and six HCs, using flow cytometric analysis of caspase 3, 8 and 9 activities.
Results: There was a trend toward higher plasma levels of soluble tumor necrosis factor (TNF)-related apoptosis-inducing ligand (sTRAIL), interleukin-10 (IL-10) and TNF-α in pAPS patients when compared with HCs. We also observed higher plasma levels of IL-10 and TNF α in APA SLE and APS SLE patients when compared with HCs. However, there was no significant difference in blood lymphocytes/monocytes apoptosis between pAPS patients and HCs.
Conclusion: There was a trend toward elevated plasma levels of sTRAIL, IL-10 and TNF-α, but no evidence for dysregulated apoptosis in pAPS patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1756-185X.13468 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship of Structural Abnormalities of Papillary Muscles to the Site of Origin of Ventricular Arrhythmias.
JACC Clin Electrophysiol
November 2024
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address:
Background: Arrhythmias originating from papillary muscles (PAPs) can be challenging when targeted with catheter ablation. The prevalence and impact of structural abnormalities on PAPs in patients with focal PAP arrhythmias is unknown.
Objectives: The purpose of this study was to analyze, in a consecutive patient series with focal PAP arrhythmias, the impact of structural abnormalities detected by multimodality imaging.
Insights into the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: findings from a cohort of 205 patients with primary APS.
Rheumatology (Oxford)
December 2024
Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
Objectives: The 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria distinguish between anticardiolipin (aCL) or anti-β2-glycoprotein I (aβ2GPI) IgG vs IgM isotypes, having isolate IgM positivity a low weight, insufficient for APS classification, and define aCL and aβ2GPI thresholds based on fixed cut-off values. We aimed to assess the performance of the 2023 ACR/EULAR criteria in a cohort of primary vascular APS patients (PAPS), previously classified according to the Sydney criteria. Additionally, we evaluated the risk of thrombotic recurrence in patients re-classified or not according to the new criteria.
View Article and Find Full Text PDFEarly subclinical macular disease in asymptomatic patients with primary antiphospholipid syndrome: A quantitative multimodal retinal evaluation.
Lupus
January 2025
Division of Rheumatology, University of Sao Paulo Medical School, Sao Paulo, Brazil.
Purpose: To perform a quantitative multimodal evaluation in 25 patients with primary antiphospholipid syndrome (PAPS) without ocular complaints and to compare them with 25 healthy individuals.
Methods: A structural and functional ophthalmological evaluation using optical coherence tomography angiography (OCTA) and microperimetry (MP) exam in 25 patients with PAPS, followed at a tertiary rheumatology outpatient clinic, was performed. All ophthalmologic manifestations were documented and subsequent statistical analysis was performed for comparative purposes, with significance set at < 0.
Anti-vitamin D antibodies.
Autoimmun Rev
January 2025
Reichman University, Herzelia, Israel; Zabludowicz Center for Autoimmune Diseases (Founder), Sheba Medical Center, Tel-Hashomer, Israel.
Background: Low vitamin D levels are commonly observed in autoimmune diseases, suggesting a potential role in disease pathogenesis. The presence of anti-vitamin D antibodies may contribute to these deficiencies and influence autoimmune processes.
Objective: To review and analyze studies investigating the occurrence of anti-vitamin D antibodies in autoimmune diseases.
Evaluating the Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs.
JCO Oncol Pract
December 2024
BC Cancer-Abbotsford, Abbotsford, BC, Canada.
Article Synopsis
- Canadian oncology patients often use patient assistance programs (PAPs) to access oncology drugs while waiting for funding, even within a universal healthcare system.
- A study reviewed the outcomes of 1,025 patients who received 40 oncology drugs, finding significant survival benefits with a median life-years gained calculated at 0.38 years for overall survival and 0.80 years for progression-free survival.
- The economic analysis revealed a total estimated value of quality-adjusted life years (QALY) gained of over $83 million, while the drug costs were about $97 million, highlighting the crucial role of PAPs in patient care and cost coverage.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!